Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.

@article{Tougeron2013EffectOL,
  title={Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer.},
  author={David Tougeron and Thierry Lecomte and J. C. Pages and Claire Villalva and Christine Collin and Aur{\'e}lie Ferru and Jean Marc Tourani and Christine Silvain and Pierre Marie Levillain and Lucie Karayan-Tapon},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2013},
  volume={24 5},
  pages={1267-73}
}
BACKGROUND Only patients with wild-type (WT) KRAS tumors benefit from anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (Mabs) in metastatic colorectal cancer (mCRC). Pyrosequencing is now widely used for the determination of KRAS mutation burden and a conservative cut-off point of 10% has been defined. Up until now, the impact of low-frequency KRAS mutations (<10%) on the response to anti-EGFR Mabs has yet to be evaluated. PATIENTS AND METHODS Tumors from patients receiving… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
37 Citations
44 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 44 references

: meta - analytical estimation and implications for therapeutic strategies

  • F Loupakis, A Ruzzo, C Cremolini
  • 2012

Similar Papers

Loading similar papers…